| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 05/19/1999 | EP0916345A1 Remedies for eating disturbance |
| 05/19/1999 | EP0916342A1 A medicament for treating obesity and improving lipid metabolism |
| 05/19/1999 | EP0915910A1 Exendin analogues, processes for their preparation and medicaments containing them |
| 05/19/1999 | EP0915860A1 Certain substituted benzylamine derivatives; a new class of neuropeptide-y1 specific ligands |
| 05/19/1999 | EP0915859A1 Certain substituted benzylamine derivatives; a new class of neuropeptide y1 specific ligands |
| 05/19/1999 | EP0915847A1 Substituted sulfonamides as selective beta3 agonists for the treatment of diabetes and obesity |
| 05/19/1999 | EP0915843A1 Azetidinone derivatives for the treatment of atheroscleroses |
| 05/19/1999 | EP0915823A1 Bi-aromatic compounds, pharmaceutical and cosmetic compositions containing same and uses |
| 05/19/1999 | EP0915706A1 Screening methods for compounds useful in the regulation of body weight |
| 05/19/1999 | EP0915700A1 Use of beta-sheet mimetics as protease and kinase inhibitors and as inhibitors of transcription factors |
| 05/19/1999 | EP0915697A2 Anticonvulsant sulfamate derivatives useful in treating obesity |
| 05/19/1999 | EP0752986B1 N-heterocyclyl sulphonamide derivatives and their use as endothelin antagonists |
| 05/19/1999 | EP0720599B1 Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
| 05/19/1999 | EP0662837B1 Use of il-10 to prevent insulin-dependent diabetes mellitus |
| 05/19/1999 | CN1217023A Canine OB protein compositions and method for recombinant prodn. |
| 05/19/1999 | CN1216995A Amphipathic molecules as cholesterol and other lipid uptake inhibitors |
| 05/19/1999 | CN1216993A Alkyl-4-silyl-phenols and esters thereof as anti-atherosclerotic agent |
| 05/19/1999 | CN1216921A Method of inhibiting vascular cell adhesion molecule-1 and treating chronic inflammatory diseases with 2,6-di-alkyl-4-silyl-phenols |
| 05/19/1999 | CN1216767A Novel 5-membered ring heterocycles, their prepn. their use and pharmaceutical preparations comprising them |
| 05/19/1999 | CN1043424C Quaternary nitrogen contg. phosphonate compounds, pharmaceutical compositions and pharmaceutical use |
| 05/18/1999 | US5905084 5-HTIF -agonists effective in treating migraine |
| 05/18/1999 | US5905075 Chromium nicotinate compositions and uses thereof |
| 05/18/1999 | CA2040884C Process for the preparation of 1-(2,3,4-trimethoxybenzyl) piperazine by reductive amination |
| 05/14/1999 | WO1999023217A1 A novel gene and uses therefor |
| 05/14/1999 | WO1999023076A1 Therapeutically active compounds based on indazole bioisostere replacement of catechol in pde4 inhibitors |
| 05/14/1999 | WO1999023072A1 Arylpiperidinopropanol and arylpiperazinopropanol derivatives and pharmaceuticals containing the same |
| 05/14/1999 | WO1999022761A1 Conjugate heat shock protein-binding peptides |
| 05/14/1999 | WO1999022754A1 Method for administering acylated insulin |
| 05/14/1999 | WO1999022752A1 Composition and method for increasing insulin activity |
| 05/14/1999 | WO1999022743A1 Poly(diallylamine)-based phosphate binders |
| 05/14/1999 | WO1999022740A1 Disaccharide derivatives for treating hyperglycaemia |
| 05/14/1999 | WO1999022738A1 Compositions of lipid lowering agents |
| 05/14/1999 | WO1999022733A1 Novel metal complexes |
| 05/14/1999 | WO1999022728A1 Methods and compositions for regulation of 5-alpha reductase activity |
| 05/14/1999 | WO1999022721A2 Unsubstituted polydiallylamine for treating hypercholesterolemia |
| 05/14/1999 | WO1999007352A3 Method for promoting expression of ldl receptor gene |
| 05/14/1999 | WO1998033904A3 An antisense oligonucleotide preparation method |
| 05/14/1999 | CA2681877A1 Arylpiperidinopropanol and arylpiperazinopropanol derivatives and pharmaceuticals containing the same |
| 05/14/1999 | CA2309175A1 Therapeutically active compounds based on indazole bioisostere replacement of catechol in pde4 inhibitors |
| 05/14/1999 | CA2308317A1 Novel metal complexes |
| 05/14/1999 | CA2308299A1 Conjugate heat shock protein-binding peptides |
| 05/14/1999 | CA2308136A1 Method for administering acylated insulin |
| 05/14/1999 | CA2307839A1 Gene involved in metabolic energy and obesity |
| 05/14/1999 | CA2307097A1 Compositions of lipid lowering agents |
| 05/12/1999 | EP0915088A1 D-Proline derivatives |
| 05/12/1999 | EP0914778A1 Oral administration of bacteria at a concentration which produces cell-mediated immunity and weight in certain animals |
| 05/12/1999 | EP0914605A1 Molecular model for vla-4 inhibitors |
| 05/12/1999 | EP0914459A2 Adenoviral mediated gene transfer in adipocytes and related implants |
| 05/12/1999 | EP0914341A1 Antagonists of intestinotrophic glp-2 peptides |
| 05/12/1999 | EP0914322A1 New indolyl and benzofuranyl carboxamides as inhibitors of nitric oxide production |
| 05/12/1999 | EP0914158A2 Pharmaceutical combination containing a compound having angiotensin ii and antagonistic activity |
| 05/12/1999 | EP0914146A1 Morphogen treatment for chronic renal failure |
| 05/12/1999 | EP0914136A1 Methods of enhancing lean tissue mass and bone mineral content and compositions therefor |
| 05/12/1999 | EP0914132A1 Eutrophic drug compositions based on transferrin glycans |
| 05/12/1999 | EP0914129A1 Use of aspirochlorine or derivatives thereof as immunosuppressive agents |
| 05/12/1999 | EP0914119A2 Solid oral dosage forms of valsartan |
| 05/12/1999 | EP0914118A1 Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators |
| 05/12/1999 | EP0914111A2 Method for the prevention and treatment of cachexia and anorexia |
| 05/12/1999 | EP0914110A1 Method of modulating microcirculation |
| 05/12/1999 | EP0914091A2 Ethene containing solutions and use thereof in methods of therapy or prophylaxis |
| 05/12/1999 | EP0735888A4 Purine compositions and methods for administration |
| 05/12/1999 | EP0733067B1 N-terminally chemically modified protein compositions and methods |
| 05/12/1999 | CN1216468A Use of dipeptidyl peptidase IV inhibitors for lowering the blood glucose level mammals |
| 05/12/1999 | CN1216248A Convalescence capsule for diabetics |
| 05/11/1999 | US5902830 Lowering plasma cholesterol levels |
| 05/11/1999 | US5902829 Administering prior to surgery a modulating mixture of l-arginine or a precursor thereof and a carrier; prevention of hypoperfusion-reperfsion injury and amelioration of hypoperfusion; substrate for nitic oxide synthetase; |
| 05/11/1999 | US5902810 Pteridine derivatives as no synthase inhibitors |
| 05/11/1999 | US5902803 5H,10H-imidazo 1,2-a!indeno 1,2-e!pyrazin-4-one derivatives, preparation thereof, and drugs containing said derivatives |
| 05/11/1999 | US5902585 Methods of inducing T cell unresponsiveness to donor tissue or organ in a recipient with GP39 antagonists |
| 05/11/1999 | US5902577 Insulin-secreting cell lines, methods of production and use |
| 05/11/1999 | CA2129541C Method of promoting nitrogen retention in humans |
| 05/11/1999 | CA2105861C Fish production |
| 05/11/1999 | CA2001889C Zinc cysteate, its preparation and uses in pharmacy and cosmetology |
| 05/06/1999 | WO1999022243A1 148 human secreted proteins |
| 05/06/1999 | WO1999021888A1 Aggregates of human insulin derivatives |
| 05/06/1999 | WO1999021857A1 3-substituted tetrahydropyridopyrimidinone derivatives, method for producing the same, and their use |
| 05/06/1999 | WO1999021835A1 QUINOLINE DERIVATIVES AS H+-ATPase INHIBITORS AND AS BONE RESORPTION INHIBITORS |
| 05/06/1999 | WO1999021617A2 Allosteric adenosine receptor modulators |
| 05/06/1999 | WO1999021578A1 Insoluble insulin compositions |
| 05/06/1999 | WO1999021573A1 Fatty acid-acylated insulin analogs |
| 05/06/1999 | WO1999021570A1 Citrus peel extract as inhibitor of acyl coa-cholesterol-o-acyltransferase, inhibitor of macrophage-lipid complex accumulation on the arterial wall and preventive or treating agent for hepatic diseases |
| 05/06/1999 | WO1999021565A1 Nutritional supplement for cerebral metabolic insufficiencies |
| 05/06/1999 | WO1999021564A1 Cyclic phosphonate ester inhibitors of microsomal triglyceride transfer protein and method |
| 05/06/1999 | WO1999021549A1 Hesperidin and hesperetin as inhibitor of acyl coa-cholesterol-o-acyltransferase, inhibitor of macrophage-lipid complex accumulation on the arterial wall and preventive or treating agent for hepatic diseases |
| 05/06/1999 | WO1999021548A1 Naringin and naringenin as inhibitor of acyl coa-cholesterol-o-acyltransferase, inhibitor of macrophage-lipid complex accumulation on the arterial wall and preventive or treating agent for hepatic diseases |
| 05/06/1999 | WO1999021540A2 Method of reducing craving in mammals |
| 05/06/1999 | WO1999021538A2 Use of glycosaminoglycans for producing pharmaceutical preparations for treating diabetes-associated diseases of the eye |
| 05/06/1999 | EP0913472A2 Human LIG-1 Homolog (HLIG-1) |
| 05/06/1999 | EP0913161A2 Diagnostic agent for diabetes |
| 05/06/1999 | EP0912741A2 T-cell selective interleukin-4 agonists |
| 05/06/1999 | EP0912739A2 Canine ob protein compositions and methods |
| 05/06/1999 | EP0912609A2 Fragments of leptin (ob protein) |
| 05/06/1999 | EP0912601A1 Suppression of immune response via inhibition of cathepsin s |
| 05/06/1999 | EP0912558A1 Substituted indazole derivatives and their use as phosphodiesterase (pde) type iv and tumor necrosis factor (tnf) inhibitors |
| 05/06/1999 | EP0912543A1 Crystalline (-)-3r,4r-trans-7-methoxy-2,2-dimethyl-3-phenyl-4-[4- 2-(pyrrolidin-1-yl)ethoxy]phenyl chromane, hydrogen fumarate |
| 05/06/1999 | EP0912523A1 Aminoguanidine carboxylate lactams for the treatment of non-insulin-dependent diabetes mellitus |
| 05/06/1999 | EP0912521A1 Substituted indazole derivatives and their use as inhibitors phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf) |
| 05/06/1999 | EP0912520A1 Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties |
| 05/06/1999 | EP0912518A1 Substituted pyridines as selective cyclooxygenase-2 inhibitors |
| 05/06/1999 | EP0912491A1 Polyol succinates and their pharmaceutical formulation |